2 enrolling by invitation. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Enrolling by invitation 2 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis FMXIN002 single dose, Epinephrine autoinjector single dose, FMXIN002 single dose + NAC - Anaphylaxis, Allergy | Phase 1 / Phase 2 | Enrolling by invitation | Nasus Pharma | 50 | 2025-11-03 | 2025-11-14 |
| A Phase I Clinical Trial to Evaluate CU-10101 Unguent CU-10101 - Atopic Dermatitis | Phase 1 | Enrolling by invitation | Cutia Therapeutics（Wuxi）Co.,Ltd | 64 | 2024-09-12 | 2026-06-10 |
Anaphylaxis (1) · Dermatitis, Atopic (1)
Hypersensitivity, Immediate (2) · Immune System Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dermatitis (1) · Genetic Diseases, Inborn (1) · Skin Diseases (1) · Skin Diseases, Eczematous (1) · Skin Diseases, Genetic (1) · Skin and Connective Tissue Diseases (1)
Epinephrine (1)
Cutia Therapeutics（Wuxi）Co.,Ltd (1) · Nasus Pharma (1)
Canada (1) · China (1)